Hepcvir is a new inhibitor which appeared in late 2013

Food and Drug Administration approved a new drug and in early 2014 the European Medicines Agency gave a registration certificate to the drug. Nucleotide RNA polymerase inhibitor is used to treat chronic hepatitis C and does not require the use of interferon (for genotype 2 and 3). Interferon causes side effects by disrupting the central nervous and cardiovascular system, gastrointestinal tract, blood clotting, and others. The inhibitor is used in combination with other antiviral drugs and is intended for adults only. Inhibitor does not carry out a monotherapy. Treatment should be combined depending on the type of the virus.

Treatment of hepatitis C is based on a combination of several antiviral drugs, depending to which genotype refers the virus. However, the main component of combination of each course is interferon. This drug is not always available and has lots of hard side effects. Moreover, not all genotypes of the virus responded to interferon. Many patients stopped taking this medication because of the severity of its adverse symptoms.  Curability was 45%. Over the past five years, several products entered the market and curability has reached 80%. Hepcvir by Cipla is a new inhibitor which appeared in late 2013. This drug can increase curability up to 97% without use of interferon.

The new preparation inhibits the proliferation of the virus and can be used for the treatment of chronic hepatitis C. The preparation was tested on a group of 1947 patients, carriers of hepatitis C virus. 97% of them showed steady positive result. A positive immune response to the drug has been noted in 12 weeks after initiation of therapy.

Side effects were observed only at half of the patients. Mostly, they noted nausea, anemia, headache, upper respiratory tract infections. None of the patients refused to undergo treatment because of the severity of side effects. The results showed that the rate of treatment will be as high as possible within a short period of time.

In the case of a combination therapy, it is forbidden to take Sofosbuvir during pregnancy. It is not advised to become pregnant during treatment with Hepcvir, and for 6 months after completion of the course. You should alert the physician about the presence of other liver problems apart from hepatitis C (liver transplant, kidney problems or the need to conduct dialysis, HIV infection).